Multiple myeloma (MM) is manifested by abnormal clonal plasma cell proliferation and accounts for approximately 1 % of all cancers and nearly 10 % of hematologic malignancies in the US. 1, 2 It is considered to be incurable, probably as a consequence of the ongoing clonal evolution over the course of disease. Although the disease remains incurable, with the introduction of autologous hematopoietic stem cell transplant (AHSCT) and novel agents, such as thalidomide, bortezomib, lenalidomide, and carfilzomib, median overall survival (OS) has increased from nearly 3 years a decade ago to over 8 years currently. 3, 4 Advances in the understanding of disease biology and better stratification of risk groups according to the genetic abnormalities have led to the development of a risk-based individualized therapeutic approach. 5 AHSCT is an effective therapy for MM and remains a standard of care in eligible patients. 6 However, the majority of patients will have disease progression or relapse at some point after AHSCT or after the initial frontline therapy. Unfortunately, patients with high-risk disease based on genetic abnormalities as well as other laboratory features are likely to relapse even faster. Maintaining response after AHSCT is an important goal and the depth of the response correlates with improved long-term outcomes, especially progression-free survival (PFS). [7] [8] [9] [10] Trying to develop strategies in order to prevent or delay disease progression or relapse has resulted in the concepts of consolidation and maintenance therapies. Consolidation is a short-term therapy administered to enhance the rate and depth of a previously obtained response. By contrast, the goal of maintenance therapy is the extension of response duration, and ultimately of PFS and OS with the use of lower doses of drugs given with minimal toxicity over a long period of time.
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Initial Studies of Maintenance in Multiple Myeloma
Over the past 40 years, several maintenance strategies for MM have 
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of melphalan with prednisone (MP), or no chemotherapy. There were no differences in the relapse rate, the remission duration, or survival among these maintenance groups. The frequencies of pneumonia and herpes zoster were higher in patients receiving continuous chemotherapy.
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In the MRC trial, after 1 year of allocated treatment, 297 survivors were randomized to either stopping all treatment until relapse, or to continue treatment with azathioprine and vincristine, interrupted every 3 months for a course of the first-allocated treatment. The overall results demonstrated a trend toward benefit with maintenance, though the differences were not statistically significant. Most of the difference was found among a few patients with unfavorable prognostic features who survived 1 year and were eligible for randomization. 12 Cohen et al. reported in 1986 on a randomized trial evaluating the impact of three approaches to consolidation and maintenance therapy after maximal response to initial therapy. All patients were treated initially with bis-chloroethylnitrosourea (BCNU), cyclophosphamide, and prednisone (BCP) until a designated level of response was achieved. Responders were randomly assigned to MP, prednisone, adriamycin, azathioprine, and vincristine (PAIV), or no therapy until relapse, followed by treatment with BCP at relapse. Initial response rates were similar to previous trials.
A small number of incremental responses were observed with both MP and PAIV. Survival was the same for all three maintenance approaches.
They concluded that additional or consolidation/maintenance therapy of the type administered in the study appears to offer little advantage once an initial response has been achieved. 13 improved with IFN, the survival benefit when seen was small and needed to be balanced with cost and toxicity.
In conclusion, long-term use of these agents was limited by toxicity and modest efficacy. The available evidence was not sufficient to recommend any of these historical strategies routinely as a maintenance approach.
Maintenance Approaches with Novel Agents
Introduction of novel therapies, including proteasome inhibitors, bortezomib, and, later, carfilzomib and the immunomodulatory agents, thalidomide, lenalidomide, and, most recently, pomalidomide, have dramatically improved OS of patients with MM. The significant efficacy of these drugs in the newly diagnosed setting, as well as in the relapsed setting, with manageable toxicities has paved the way for maintenance trials with these drugs.
Thalidomide
Thalidomide was the first immunomodulatory agent that showed efficacy in the treatment of MM. 20, 21 It has been studied as a maintenance therapy in clinical trials, either as a single agent or combined with corticosteroids or other agents with varying efficacy (see Table 1 secondary endpoints were myeloma-specific PFS, PFS, incidence of venous thromboembolism, and health-related quality of life (HRQoL). With a median follow-up of 4.1 years, no differences in OS between thalidomideprednisone and observation were detected; thalidomide-prednisone was associated with superior myeloma-specific PFS and PFS (4-year estimates were 32 % versus 14 %) and more frequent venous thromboembolism (7.3 % versus none). Those allocated to thalidomide-prednisone reported worse HRQoL with respect to cognitive function, dyspnea, constipation, thirst, leg swelling, numbness, dry mouth, and balance problems. In conclusion, thalidomide maintenance certainly prolonged PFS but had a variable impact on OS. The variability in OS benefit likely reflects the heterogeneity among the studies and the availability of effective salvage therapies. While prolonging PFS, in one study it significantly diminished patient-reported health-related quality of life. An important thing to emphasize is that 'worse' OS was documented in some trials among the high-risk patients.
Bortezomib
Bortezomib is a proteasome inhibitor, which has efficacy in treatment of both newly diagnosed and relapsed MM. 33, 34 It has been studied as a maintenance therapy in clinical trials, either as a single agent in combination with corticosteroids or other agents with varying efficacy (see Table 2 ).
Bortezomib was evaluated as a maintenance therapy after AHSCT in the HOVON-65/GMMG-HD4 trial, where 827 eligible patients with newly diagnosed symptomatic MM were randomly assigned to receive induction therapy with VAD or bortezomib, doxorubicin, and dexamethasone (PAD), followed by high-dose melphalan and AHSCT. months versus not reached at 54 months). In the thalidomide arm, 64 % of the patients discontinued maintenance therapy because of progressive disease (PD), toxicity, and other reasons (31 %, 31 %, and 2 %, respectively).
In the bortezomib arm, 47% discontinued maintenance therapy because of PD, toxicity, and other reasons (29 %, 9 %, and 9 %, respectively). Grade 3-4 PNP rate was significantly greater in the PAD group (16 % versus 7 %). 35 However, given the study design, it is hard to differentiate if the benefit came from the introduction of bortezomib as part of induction or maintenance or both. 
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Lenalidomide
Lenalidomide was the second immunomodulatory drug, which showed efficacy for the treatment of both newly diagnosed and relapsed myeloma. 40, 41 It has a stronger antimyeloma effect and a more favorable toxicity profile compared with thalidomide. 1 It is considered a feasible maintenance treatment because it is an oral agent, has efficacy in low doses, and, as a single agent, can be given orally and has a well-defined toxicity profile. Efficacy of lenalidomide as a maintenance therapy was evaluated in phase III, double-blind, randomized trials, which included both transplant-eligible and ineligible patients (see Table 3 ).
In the IFM 05-02 study, patients having received previous induction therapy with either vincristine, doxorubicin, plus dexamethasone or bortezomib plus dexamethasone (VD) followed by one or two AHSCT were treated with two cycles of lenalidomide consolidation therapy and were, thereafter, randomized to lenalidomide maintenance (LM) (10-15 mg daily) or placebo until disease progression. After a median follow-up of 45 months from randomization, the 4-year estimates of PFS were 43 % for the lenalidomide group and 22 % for the placebo group, while no difference in OS was seen between the two groups (73 % versus 75 %). The study was unblinded at median follow-up of 32 months and all maintenance was stopped at a median time of 32 months for the lenalidomide arm due to concern regarding the development of second primary malignancy (SPM).
The placebo group patients did not crossover to receive lenalidomide at unblinding. The lenalidomide group had an increased incidence of hematologic toxicities (primarily neutropenia) and an increase in the LM group. The study showed that although LM therapy was associated with more toxicity and SPMs, the patients benefited from significantly longer PFS and improved OS. 
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LM was also assessed in the setting of transplant-ineligible patients.
The MM-015 study randomized elderly patients not eligible for AHSCT to receive either MP or MPR, both given for nine cycles, followed by placebo, or MPR for nine cycles, followed by LM (MPR-R) until disease progression.
PFS was similar for the MP and MPR arm, but was significantly longer for patients receiving MPR-R (13 months versus 14 months versus 31 months, respectively 
Summary and Recommendations
The landscape of myeloma treatments continues to evolve rapidly with the introduction of new drugs. The question of maintenance is entwined with the question as to the ideal duration of therapy. From our experience so far, we realize that myeloma continues to relapse after the most aggressive treatment approaches. Given this background, the interest in continuing to intensify treatment of the disease is clearly understandable. Addition of more drugs to the current regimens do not necessarily translate into more benefit as was shown with the bortezomib, dexamethasone, cyclophosphamide, and lenalidomide (CRVD) and bortezomib, dexamethasone, cyclophosphamide, and thalidomide (CTVD) combinations in clinical trials. Instead of intensifying the regimen, an alternate approach would be to give a more tolerated combination for a longer time, still achieving the goal of maximal tumor reduction. In the patient undergoing an autologous stem cell transplant, this prolonged course of treatment is considered a maintenance, whereas in the nontransplanted patients, it represents continued therapy, bringing up the question of ideal therapy duration.
Given the seemingly contradictory data, definitive conclusions remain difficult to make. However, taking into account the benefit shown in the US phase III trial among those not achieving a CR/very good partial response (VGPR), it is reasonable to consider offering maintenance (aka prolonged therapy). Such patients can certainly be considered for LM.
However, in the high-risk patients prolonged treatment with bortezomibbased regimens appear to be justified based on the HOVON data examining the role of PAD. We recommend putting patients with highrisk myeloma on a bortezomib maintenance. For the remaining patients, one could consider a short consolidation as shown in the French trial:
namely, two cycles of lenalidomide-dexamethasone with no continued therapy, given that this trial failed to show any difference in OS. Clearly, newer trials such as the one using oral proteasome inhibitor ixazomib would be of great interest. n
